Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.5	-	10	-	49.3
Cost of Revenue	0.13	-	2.57	-1.13	24.21
Gross Profit	0.37	-	7.43	1.13	25.09
Selling, General & Admin	23.01	26.43	18.42	23.64	21.54
Research & Development	17.77	20.93	17.42	30.2	31.85
Other Operating Expenses	-0.3	-	0.01	-	-
Total Operating Expenses	40.47	47.36	35.85	53.84	53.39
Operating Income	-40.11	-47.36	-28.42	-52.71	-28.31
Interest Income	2.17	3.04	2.13	0.84	0
Interest Expense	-0.26	-1.37	-2.88	-3.52	-5.44
Other Non-Operating Income (Expense)	-3.69	2.44	-0.82	12.88	53
Total Non-Operating Income (Expense)	-1.77	4.11	-1.57	10.2	47.56
Pretax Income	-41.88	-43.25	-30	-42.51	19.25
Provision for Income Taxes	-	-	-0.53	-2.29	2.05
Net Income	-41.88	-43.25	-29.47	-40.21	17.2
Net Income to Common	-41.88	-43.25	-29.47	-40.21	17.2
Shares Outstanding (Basic)	159	148	132	121	106
Shares Outstanding (Diluted)	159	148	132	121	111
Shares Change (YoY)	7.77%	12.16%	9.33%	8.63%	63.82%
EPS (Basic)	-0.25	-0.30	-0.32	-0.36	0.14
EPS (Diluted)	-0.25	-0.30	-0.32	-0.36	-0.34
Shares Outstanding	159.13	155.15	140.06	124.99	116.98
Free Cash Flow	-30.99	-32.83	-22.44	-46.98	-7.81
Free Cash Flow Per Share	-0.19	-0.22	-0.17	-0.39	-0.07
Gross Margin	73.40%	-	74.26%	-	50.89%
Operating Margin	-8021.40%	-	-284.16%	-	-57.42%
Profit Margin	-8375.60%	-	-294.66%	-	34.90%
FCF Margin	-6198.20%	-	-224.43%	-	-15.83%
EBITDA	-38.96	-46.28	-27.34	-51.83	-27.44
EBITDA Margin	-7791.60%	-	-273.38%	-	-55.65%
EBIT	-40.11	-47.36	-28.42	-52.71	-28.31
EBIT Margin	-8021.40%	-	-284.16%	-	-57.42%
Effective Tax Rate	0.00%	0.00%	1.77%	5.40%	10.65%

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q